It was announced today at the ERS Congress in Madrid that studies have shown Nintedanib (an anti-fibrotic drug used to slow down the progression of IPF) works on many other types of progressive Pulmonary Fibrosis.
The results of this clinical trial will now be reviewed by NICE who will then decide if Nintedanib can be used for more than IPF in the UK.
The PF Trust worked closely with Boehringer Ingelheim (the manufacturer of Nintedanib) as part of the patient advisory board on the lay report for this breakthrough.
Ron Flewett, Trustee of the PF Trust says, “what fantastic news for sufferers with progressive pulmonary fibrosis. This is a step in the right direction and I hope the drug helps others as it has helped myself enormously.”